Published in Clin Exp Immunol on August 01, 2000
Pathogenesis of Afa/Dr diffusely adhering Escherichia coli. Clin Microbiol Rev (2005) 1.51
Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59. J Autoimmun (2014) 0.91
The protective role of CD59 and pathogenic role of complement in hepatic ischemia and reperfusion injury. Am J Pathol (2011) 0.90
Effect of IL-4 on altered expression of complement activation regulators in rat pancreatic cells during severe acute pancreatitis. World J Gastroenterol (2005) 0.89
NF-κB and enhancer-binding CREB protein scaffolded by CREB-binding protein (CBP)/p300 proteins regulate CD59 protein expression to protect cells from complement attack. J Biol Chem (2013) 0.86
Complement mediated hepatocytes injury in a model of autoantibody induced hepatitis. Immunobiology (2010) 0.85
Identification of a Naegleria fowleri membrane protein reactive with anti-human CD59 antibody. Infect Immun (2006) 0.81
Constitutive expression of murine decay-accelerating factor 1 is controlled by the transcription factor Sp1. J Immunol (2006) 0.81
Triggering of the dsRNA sensors TLR3, MDA5, and RIG-I induces CD55 expression in synovial fibroblasts. PLoS One (2012) 0.81
Selective aryl hydrocarbon receptor modulator-mediated repression of CD55 expression induced by cytokine exposure. J Pharmacol Exp Ther (2012) 0.81
Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles. J Virol (2013) 0.80
Pathogenesis of human diffusely adhering Escherichia coli expressing Afa/Dr adhesins (Afa/Dr DAEC): current insights and future challenges. Clin Microbiol Rev (2014) 0.79
Bioinformatic analysis of the membrane cofactor protein CD46 and microRNA expression in hepatocellular carcinoma. Oncol Rep (2013) 0.78
Hepatitis B virus X protein up-regulates C4b-binding protein α through activating transcription factor Sp1 in protection of hepatoma cells from complement attack. Oncotarget (2016) 0.77
Differential regulation of protein expression in response to polyunsaturated fatty acids in the liver of apoE-knockout mice and in HepG2 cells. J Biomed Sci (2015) 0.77
A tandem repeat in decay accelerating factor 1 is associated with severity of murine mercury-induced autoimmunity. Autoimmune Dis (2014) 0.75
Complement alternative pathway activation in human nonalcoholic steatohepatitis. PLoS One (2014) 0.75
IL‑6 and IL‑8 enhance factor H binding to the cell membranes. Mol Med Rep (2016) 0.75
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
The acute phase response. Immunol Today (1994) 7.53
Biosynthesis of complement. Adv Immunol (1976) 2.36
Cytokines and the hepatic acute-phase response. Semin Liver Dis (1999) 2.17
New insights into the biology of the acute phase response. J Clin Immunol (1999) 2.05
Cytokine expression by neutrophils and macrophages in vivo: endotoxin induces tumor necrosis factor-alpha, macrophage inflammatory protein-2, interleukin-1 beta, and interleukin-6 but not RANTES or transforming growth factor-beta 1 mRNA expression in acute lung inflammation. Am J Respir Cell Mol Biol (1994) 1.99
Complement biosynthesis by the human hepatoma-derived cell line HepG2. J Clin Invest (1982) 1.75
Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol (1996) 1.36
The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. APMIS (1998) 1.24
Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol (1998) 1.16
Alpha 1-acid glycoprotein potentiates lipopolysaccharide-induced secretion of interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha by human monocytes and alveolar and peritoneal macrophages. Eur J Immunol (1992) 1.15
Interleukin 4 acts as an inducer of decay-accelerating factor gene expression in human intestinal epithelial cells. Gastroenterology (1996) 1.11
Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood (1999) 1.10
Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies. J Clin Lab Immunol (1992) 1.07
Effect of interferon-gamma on complement gene expression in different cell types. Biochem J (1992) 1.03
Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46(MCP), CD55(DAF), and CD59 on human vascular endothelial cells. Lymphokine Cytokine Res (1993) 1.01
Isoforms of human C4b-binding protein. I. Molecular basis for the C4BP isoform pattern and its variations in human plasma. J Immunol (1995) 0.97
Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. Cancer Immunol Immunother (1996) 0.96
Transcriptional regulation of complement genes. Annu Rev Immunol (1995) 0.96
Complement and complement deficiencies. Semin Liver Dis (1997) 0.94
Cytokines modulate expression of cell-membrane complement inhibitory proteins in human lung cancer cell lines. Am J Respir Cell Mol Biol (1998) 0.94
Development of a model for cytomegalovirus infection of oligodendrocytes. J Gen Virol (1997) 0.91
Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells. Clin Exp Immunol (1998) 0.89
Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes. J Neuroimmunol (1993) 0.89
Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes. Immunology (1996) 0.87
Immunostaining for membrane attack complex of complement is related to cell necrosis in fulminant and acute hepatitis. Gastroenterology (1995) 0.86
Isoforms of human C4b-binding protein. II. Differential modulation of the C4BPA and C4BPB genes by acute phase cytokines. J Immunol (1995) 0.85
Tumour necrosis factor-alpha up-regulates decay-accelerating factor gene expression in human intestinal epithelial cells. Immunology (1997) 0.85
Transforming growth factor-beta isoforms regulate the surface expression of membrane cofactor protein (CD46) and CD59 on human keratinocytes [corrected]. Eur J Immunol (1999) 0.85
Effect of cytokines on the secretion of the fifth and eighth complement components by HepG2 cells. Int J Clin Lab Res (1994) 0.84
Characterization of the 5' flanking region of the human complement factor H gene. Scand J Immunol (1997) 0.83
The influence of tumour necrosis factor-alpha, interleukin-1 beta and interferon-gamma on the expression and function of the complement regulatory protein CD59 on the human colonic adenocarcinoma cell line HT29. Scand J Immunol (1995) 0.83
Wheat germ agglutinin and other selected lectins increase synthesis of decay-accelerating factor in human endothelial cells. J Immunol (1991) 0.83
The role of complement activation in tumour necrosis factor-induced lethal hepatitis. Cytokine (1999) 0.80
Expression of the human complement C8 subunits is independently regulated by interleukin 1 beta, interleukin 6, and interferon gamma. Immunopharmacology (1997) 0.80
Interleukin 6 upregulates TNF-alpha-dependent C3-stimulating activity through enhancement of TNF-alpha specific binding on rat liver epithelial cells. Cytokine (1996) 0.78
Lack of effect of different cytokines on expression of membrane-bound regulators of complement activity on human uveal melanoma cells. J Interferon Cytokine Res (1997) 0.78
Modulation of C4b-binding protein isoforms during the acute phase response caused by orthopedic surgery. Haemostasis (1997) 0.76
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
Crystal structure of human homogentisate dioxygenase. Nat Struct Biol (2000) 2.16
Immunoaffinity purification of human complement component C9 using monoclonal antibodies. J Immunol Methods (1983) 2.11
Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol (1987) 1.92
Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with a very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59. Biochemistry (1994) 1.84
Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood (2001) 1.65
Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59. J Exp Med (1997) 1.65
The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol (1993) 1.59
Monoclonal antibodies demonstrate protection of polymorphonuclear leukocytes against complement attack. Nature (1985) 1.59
Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol (2001) 1.58
Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology (2000) 1.56
Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature (1989) 1.49
The recovery of human polymorphonuclear leucocytes from sublytic complement attack is mediated by changes in intracellular free calcium. Biochem J (1985) 1.49
Innate recognition of bacteria in human milk is mediated by a milk-derived highly expressed pattern recognition receptor, soluble CD14. J Exp Med (2000) 1.48
Role and regulation of pig CD59 and membrane cofactor protein/CD46 expressed on pig aortic endothelial cells. Transplantation (2000) 1.43
Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. Biochem J (1992) 1.43
A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results. J Neurol Neurosurg Psychiatry (1987) 1.42
Perforin is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain. EMBO J (1997) 1.42
The preparation and characterization of monoclonal antibodies to human complement component C8 and their use in purification of C8 and C8 subunits. Biochem J (1988) 1.41
Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol (1997) 1.41
Exogenous glycosyl phosphatidylinositol-anchored CD59 associates with kinases in membrane clusters on U937 cells and becomes Ca(2+)-signaling competent. J Cell Biol (1995) 1.40
Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol (1995) 1.35
Inhibition of complement-induced [14C]sucrose release by intracellular and extracellular monoclonal antibodies to C9: evidence that C9 is a transmembrane protein. Biochem Biophys Res Commun (1984) 1.33
Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp Neurol (1999) 1.32
Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol (1994) 1.30
Tissue distribution of complement regulatory membrane proteins in rats. Immunology (1994) 1.29
The glycosylation of the complement regulatory protein, human erythrocyte CD59. J Biol Chem (1997) 1.28
Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am J Pathol (2000) 1.27
Human factor H-related protein 5 (FHR-5). A new complement-associated protein. J Biol Chem (2000) 1.26
Intracellular Ca2+ and cell injury: a paradoxical role of Ca2+ in complement membrane attack. Cell Calcium (1986) 1.25
Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. Am J Pathol (1994) 1.24
Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals. Clin Exp Immunol (1991) 1.22
The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol (1998) 1.22
Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol (1996) 1.21
Myelin-oligodendrocyte glycoprotein (MOG) is a surface marker of oligodendrocyte maturation. J Neuroimmunol (1989) 1.20
Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities. Immunology (2000) 1.19
Complement regulation at the molecular level: the structure of decay-accelerating factor. Proc Natl Acad Sci U S A (2004) 1.17
Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol (2008) 1.17
Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. Immunology (1992) 1.17
Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J Immunol (1995) 1.14
Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Complement activation and attack in the absence of anti-myelin antibodies. J Neurol Sci (1989) 1.13
The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain (1989) 1.13
Stimulation of human rheumatoid synovial cells by non-lethal complement membrane attack. Immunology (1990) 1.12
Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood (1999) 1.10
Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement. J Clin Invest (1995) 1.10
Structural and functional analysis of mutations in alkaptonuria. Hum Mol Genet (2000) 1.10
Efficient generation of monoclonal antibodies against surface-expressed proteins by hyperexpression in rodent cells. J Immunol Methods (1999) 1.09
Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis Rheum (2004) 1.09
Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis. Clin Exp Immunol (2009) 1.09
Immunoradiometric assay for human complement component C9 utilising monoclonal antibodies. Clin Chim Acta (1983) 1.08
Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59. J Immunol (1997) 1.08
Sphingomyelinases in the venom of the spider Loxosceles intermedia are responsible for both dermonecrosis and complement-dependent hemolysis. Biochem Biophys Res Commun (1998) 1.08
Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies. J Clin Lab Immunol (1992) 1.07
Molecular and functional analysis of mouse decay accelerating factor (CD55). Biochem J (1999) 1.07
Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. Ann Neurol (1999) 1.07
In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats. J Exp Med (1994) 1.06
Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion on lipopolysaccharide release. Lancet (1992) 1.06
Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol (1989) 1.05
Reversible cell damage by T-cell perforins. Calcium influx and propidium iodide uptake into K562 cells in the absence of lysis. Biochem J (1990) 1.05
Complement mediated cell death is associated with DNA fragmentation. Cell Death Differ (2000) 1.05
Apoptosis is associated with reduced expression of complement regulatory molecules, adhesion molecules and other receptors on polymorphonuclear leucocytes: functional relevance and role in inflammation. Immunology (1995) 1.05
Complement-inhibiting activities of human CD59 and analogues from rat, sheep, and pig are not homologously restricted. J Immunol (1994) 1.04
Sub-lytic C5b-9 induces functional changes in retinal pigment epithelial cells consistent with age-related macular degeneration. Eye (Lond) (2011) 1.04
Properties of a low molecular weight complement component C6 found in human subjects with subtotal C6 deficiency. Immunology (1992) 1.03
Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site. Biochem J (1994) 1.03
Membrane attack complex (MAC)-mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC inhibitory proteins. Immunology (1992) 1.02
Molecular cloning and functional characterization of the rat analogue of human decay-accelerating factor (CD55). J Immunol (1998) 1.02
Identification and characterization of complement C3 receptors on human astrocytes. J Immunol (1996) 1.01
Tissue distribution of the rat analogue of decay-accelerating factor. Immunology (1999) 1.01
Differential expression of individual complement regulators in the brain and choroid plexus. Lab Invest (1999) 0.99
Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation. Clin Exp Immunol (1991) 0.99
Expression of the glycosylphosphatidylinositol-linked complement-inhibiting protein CD59 antigen in insect cells using a baculovirus vector. Biochem J (1993) 0.99
The sheep analogue of human CD59: purification and characterization of its complement inhibitory activity. Immunology (1993) 0.99
Immunolocalization of complement component C9 on necrotic and non-necrotic muscle fibres in myositis using monoclonal antibodies: a primary role of complement in autoimmune cell damage. Immunology (1984) 0.99
Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J Immunol (1995) 0.98
The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells. Clin Exp Immunol (1991) 0.98
Analysis of the developmental SIX6 homeobox gene in patients with anophthalmia/microphthalmia. Am J Med Genet A (2004) 0.98
Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis. Lancet (1984) 0.98
2-Chloroadenosine inhibits complement-induced reactive oxygen metabolite production and recovery of human polymorphonuclear leucocytes attacked by complement. Biochem Biophys Res Commun (1985) 0.97
Immunohistochemical localisation of terminal complement component C9 in experimental allergic encephalomyelitis. Acta Neuropathol (1989) 0.97
Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin Exp Immunol (2002) 0.97
Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the rat. Arthritis Rheum (2000) 0.97
CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats. J Am Soc Nephrol (1998) 0.97
Echoviruses and coxsackie B viruses that use human decay-accelerating factor (DAF) as a receptor do not bind the rodent analogues of DAF. J Infect Dis (2000) 0.96
Molecular bases of combined subtotal deficiencies of C6 and C7: their effects in combination with other C6 and C7 deficiencies. J Immunol (1996) 0.96
Terminal complement complexes and C1/C1 inhibitor complexes in autoimmune thyroid disease. Clin Exp Immunol (1989) 0.96
Expression of complement regulatory molecules and other surface markers on neutrophils from synovial fluid and blood of patients with rheumatoid arthritis. Br J Rheumatol (1994) 0.96
Complement lysis of U937, a nucleated mammalian cell line in the absence of C9: effect of C9 on C5b-8 mediated cell lysis. J Immunol (1986) 0.96
Complement activation and inhibition in experimental models of arthritis. Mol Immunol (2000) 0.95
The ninth complement component in rheumatoid arthritis, Behçet's disease and other rheumatic diseases. Br J Rheumatol (1986) 0.95
Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis. J Immunol (1995) 0.95
Reversible injury of cultured rat oligodendrocytes by complement. Immunology (1989) 0.95
Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells. Eur J Immunol (1996) 0.94
Role of complement in the aetiology of Pick's disease? J Neuropathol Exp Neurol (1996) 0.94
Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis. Clin Exp Immunol (1997) 0.93
Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells. Kidney Int (1995) 0.93
Functional analysis of MCCA and MCCB mutations causing methylcrotonylglycinuria. Mol Genet Metab (2003) 0.92